Avior Wealth Management LLC Lowers Stock Holdings in Insulet Co. (NASDAQ:PODD)

Avior Wealth Management LLC lowered its stake in Insulet Co. (NASDAQ:PODD) by 16.1% during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 2,409 shares of the medical instruments supplier’s stock after selling 462 shares during the period. Avior Wealth Management LLC’s holdings in Insulet were worth $629,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Blue Trust Inc. grew its stake in shares of Insulet by 84.1% in the third quarter. Blue Trust Inc. now owns 127 shares of the medical instruments supplier’s stock worth $30,000 after acquiring an additional 58 shares during the last quarter. Venturi Wealth Management LLC grew its position in Insulet by 633.3% during the 3rd quarter. Venturi Wealth Management LLC now owns 154 shares of the medical instruments supplier’s stock valued at $36,000 after purchasing an additional 133 shares during the last quarter. TD Private Client Wealth LLC increased its stake in Insulet by 32.6% during the 3rd quarter. TD Private Client Wealth LLC now owns 228 shares of the medical instruments supplier’s stock valued at $53,000 after purchasing an additional 56 shares in the last quarter. Friedenthal Financial purchased a new position in Insulet in the fourth quarter worth about $57,000. Finally, Versant Capital Management Inc raised its holdings in Insulet by 106.1% in the fourth quarter. Versant Capital Management Inc now owns 305 shares of the medical instruments supplier’s stock worth $80,000 after buying an additional 157 shares during the last quarter.

Insulet Stock Performance

NASDAQ:PODD opened at $280.35 on Friday. The company has a debt-to-equity ratio of 1.21, a quick ratio of 2.80 and a current ratio of 3.68. The stock has a 50-day simple moving average of $267.25 and a two-hundred day simple moving average of $235.53. The firm has a market capitalization of $19.66 billion, a PE ratio of 48.01, a P/E/G ratio of 3.50 and a beta of 1.22. Insulet Co. has a 52-week low of $160.19 and a 52-week high of $282.86.

Insulet (NASDAQ:PODD) last announced its quarterly earnings data on Thursday, November 7th. The medical instruments supplier reported $0.90 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.77 by $0.13. Insulet had a return on equity of 27.98% and a net margin of 21.22%. The company had revenue of $543.90 million during the quarter, compared to the consensus estimate of $518.50 million. During the same period in the previous year, the company posted $0.71 EPS. Analysts forecast that Insulet Co. will post 3.22 EPS for the current year.

Analyst Ratings Changes

Several equities research analysts recently weighed in on the stock. Wells Fargo & Company raised their price target on shares of Insulet from $290.00 to $305.00 and gave the company an “overweight” rating in a research report on Wednesday, December 11th. Sanford C. Bernstein assumed coverage on Insulet in a report on Wednesday, November 6th. They issued an “outperform” rating and a $300.00 target price for the company. Canaccord Genuity Group upped their price target on Insulet from $269.00 to $304.00 and gave the company a “buy” rating in a report on Monday, December 9th. Morgan Stanley lifted their price objective on Insulet from $234.00 to $317.00 and gave the stock an “overweight” rating in a report on Monday, November 11th. Finally, Barclays upped their target price on shares of Insulet from $220.00 to $234.00 and gave the company an “equal weight” rating in a research note on Monday, November 11th. Three investment analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $272.81.

Insider Activity

In related news, CAO Lauren Budden sold 915 shares of the firm’s stock in a transaction on Tuesday, December 10th. The shares were sold at an average price of $275.62, for a total transaction of $252,192.30. Following the completion of the transaction, the chief accounting officer now directly owns 5,733 shares of the company’s stock, valued at approximately $1,580,129.46. This trade represents a 13.76 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Eric Benjamin sold 12,394 shares of the business’s stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $280.00, for a total value of $3,470,320.00. Following the completion of the sale, the executive vice president now owns 11,383 shares in the company, valued at $3,187,240. This represents a 52.13 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 0.47% of the company’s stock.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.